Date: 2016-01-07
Type of information: Plant acquisition
Compound: US biologics manufacturing facility
Company: Takeda Pharmaceutical (Japan) Baxalta (USA - IL)
Therapeutic area:
Type agreement: plant acquisition
Action mechanism:
Disease:
Details: * On January 6, 2016, Takeda Pharmaceutical Company announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota,U.S., from Baxalta. Takeda intends to use the facility primarily for the manufactureof Entyvio®(vedolizumab) and other biologic products, allowing the company to maximize global
efficiencies and further enhance the product’s supply chain flexibility. The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities forthe manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.
Financial terms:
Latest news:
